Towards Evolutionary-based Automated Machine Learning for Small Molecule Pharmacokinetic Prediction

• URL: http://arxiv.org/abs/2408.00421v1
• Date: Thu, 1 Aug 2024 09:46:06 GMT
• Title: Towards Evolutionary-based Automated Machine Learning for Small Molecule Pharmacokinetic Prediction
• Authors: Alex G. C. de Sá, David B. Ascher,
• Abstract summary: Small molecule properties are crucial in the early stages of drug development. Existing methods lack personalisation and rely on manually crafted ML algorithms or pipelines. We propose a novel evolutionary-based automated ML method (AutoML) specifically designed for predicting small molecule properties.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-nd/4.0/
• Abstract: Machine learning (ML) is revolutionising drug discovery by expediting the prediction of small molecule properties essential for developing new drugs. These properties -- including absorption, distribution, metabolism and excretion (ADME)-- are crucial in the early stages of drug development since they provide an understanding of the course of the drug in the organism, i.e., the drug's pharmacokinetics. However, existing methods lack personalisation and rely on manually crafted ML algorithms or pipelines, which can introduce inefficiencies and biases into the process. To address these challenges, we propose a novel evolutionary-based automated ML method (AutoML) specifically designed for predicting small molecule properties, with a particular focus on pharmacokinetics. Leveraging the advantages of grammar-based genetic programming, our AutoML method streamlines the process by automatically selecting algorithms and designing predictive pipelines tailored to the particular characteristics of input molecular data. Results demonstrate AutoML's effectiveness in selecting diverse ML algorithms, resulting in comparable or even improved predictive performances compared to conventional approaches. By offering personalised ML-driven pipelines, our method promises to enhance small molecule research in drug discovery, providing researchers with a valuable tool for accelerating the development of novel therapeutic drugs.

Related papers

• DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration [31.892593155710625]
  We introduce DrugAgent, a multi-agent framework aimed at automating machine learning (ML) programming in drug discovery. DrugAgent incorporates domain expertise by identifying specific requirements and building domain-specific tools, while systematically exploring different ideas to find effective solutions. For example, DrugAgent is able to complete the ML programming pipeline end-to-end, from data acquisition to performance evaluation for the ADMET prediction task, and finally select the best model.
  arXiv  Detail & Related papers  (2024-11-24T03:06:59Z)
• Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials [49.19897427783105]
  The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes.
  arXiv  Detail & Related papers  (2024-09-06T02:03:38Z)
• Physical formula enhanced multi-task learning for pharmacokinetics prediction [54.13787789006417]
  A major challenge for AI-driven drug discovery is the scarcity of high-quality data. We develop a formula enhanced mul-ti-task learning (PEMAL) method that predicts four key parameters of pharmacokinetics simultaneously. Our experiments reveal that PEMAL significantly lowers the data demand, compared to typical Graph Neural Networks.
  arXiv  Detail & Related papers  (2024-04-16T07:42:55Z)
• Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks [2.6062146828550903]
  We have developed a Generative AI (GM) workflow based on a variational autoencoder and active learning steps. The designed GM workflow iteratively learns from molecular metrics, including drug likeliness, synthesizability, similarity, and docking scores. The proportion of high-affinity molecules inferred by our GM workflow was significantly greater than that in the training data.
  arXiv  Detail & Related papers  (2023-05-04T13:25:14Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• Improving Molecular Representation Learning with Metric Learning-enhanced Optimal Transport [49.237577649802034]
  We develop a novel optimal transport-based algorithm termed MROT to enhance their generalization capability for molecular regression problems. MROT significantly outperforms state-of-the-art models, showing promising potential in accelerating the discovery of new substances.
  arXiv  Detail & Related papers  (2022-02-13T04:56:18Z)
• Molecular Attributes Transfer from Non-Parallel Data [57.010952598634944]
  We formulate molecular optimization as a style transfer problem and present a novel generative model that could automatically learn internal differences between two groups of non-parallel data. Experiments on two molecular optimization tasks, toxicity modification and synthesizability improvement, demonstrate that our model significantly outperforms several state-of-the-art methods.
  arXiv  Detail & Related papers  (2021-11-30T06:10:22Z)
• Artificial Intelligence based Autonomous Molecular Design for Medical Therapeutic: A Perspective [9.371378627575883]
  Domain-aware machine learning (ML) models have been increasingly adopted for accelerating small molecule therapeutic design. We present the most recent breakthrough achieved by each of the components, and how such autonomous AI and ML workflow can be realized.
  arXiv  Detail & Related papers  (2021-02-10T00:43:46Z)
• Deep Learning for Virtual Screening: Five Reasons to Use ROC Cost Functions [80.12620331438052]
  deep learning has become an important tool for rapid screening of billions of molecules in silico for potential hits containing desired chemical features. Despite its importance, substantial challenges persist in training these models, such as severe class imbalance, high decision thresholds, and lack of ground truth labels in some datasets. We argue in favor of directly optimizing the receiver operating characteristic (ROC) in such cases, due to its robustness to class imbalance.
  arXiv  Detail & Related papers  (2020-06-25T08:46:37Z)
• Predicting drug properties with parameter-free machine learning: Pareto-Optimal Embedded Modeling (POEM) [0.13854111346209866]
  We describe a similarity-based method for predicting molecular properties. POEM is a non-parametric, supervised ML algorithm developed to generate reliable predictive models without need for optimization. We benchmark POEM relative to industry-standard ML algorithms and published results across 17 classifications tasks. POEM performs well in all cases and reduces the risk of overfitting.
  arXiv  Detail & Related papers  (2020-02-11T17:20:28Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.